Posted by Michael Wonder on 06 Nov 2015
European Medicines Agency validates Bristol-Myers Squibb’s type II variation application for Opdivo (nivolumab) in previously treated advanced renal cell carcinoma
5 November 2015 - Validation of the application confirms the submission is complete and begins the EMA’s centralized review process.
For more details, go to: http://news.bms.com/press-release/european-medicines-agency-validates-bristol-myers-squibbs-type-ii-variation-applicatio
